Poland Diabetes Therapeutics Market Analysis

Poland Diabetes Therapeutics Market Executive Analysis

Poland's diabetes therapeutics market is expected to witness growth from $835 Mn in 2022 to $1,809 Mn in 2030 with a CAGR of 10.15% for the forecasted year 2022-30. The budget for 2023 anticipates a rise in healthcare spending to nearly 6 % of GDP. Approximately $18.53 Bn was spent on health protection in 2015. In 2023, Poland expects to expand to about $39 Bn. At the end of 2015, when Poland assumed control of the government, the sum spent on health services accounted for almost 4.5 % of the GDP. They will surpass the 6 %age points promised in the following year, 2023. Following the statutory procedure, which has been in use for years, Poland pledged to contribute 6% of its GDP.

More than 2.5 Million people in Poland are dealing with diabetes. Currently, there is a lot of effort being made to improve the quality of life for those who have diabetes. This work is mostly focused on the creation of ever-improving glycemic control systems, insulin pumps, and smartphone apps that make life easier for those with diabetes. The development of transplantology research, including pancreas or pancreatic islet transplantation, autologous bone marrow transplantation, autologous stem cell transplantation, or T-regulatory cell therapy, is the second crucial component. Finally, 3D printing research is being done to create a bionic pancreas. It is important to consider the stage at which work on unique solutions is progressing.

In recent years, the market for insulin pumps has expanded dramatically. To control most insulin delivery devices, continuous glucose monitoring systems are typically combined with them. Based on the value of glycemia and the trend, they operate using ever-improving mathematical algorithms for administering insulin. A two-hormonal pump that can provide glucagon in the event of underexposure to insulin is a novel system that can be referred to as an artificial pancreas. The pump has been under construction for a long time. T-regulatory cell treatment is a minimally invasive technique for halting the disease's progression. T-regulatory cells are a subset of T lymphocytes that are responsible for controlling the immune system's level of response. It makes perfect sense to use them when diabetes causes the immune system to react excessively, destroying pancreatic islets.

Market Dynamics

Market Growth Drivers

Diabetes medicines are increasingly in demand as diabetes prevalence has risen in Poland in recent years. Poland had over 2.2 Mn persons with diabetes in 2019; the International Diabetes Federation predicts that the figure would rise to 2.8 Mn by 2045. The market for diabetic therapies is expanding in Poland, which is also a result of the country's ageing population. The prevalence of diabetes is higher in older persons, and as the population ages, so is the need for diabetic therapies.  The construction of diabetic clinics and the payment of some diabetes drugs are just two of the steps the Polish government has put in place to enhance diabetes care and treatment. The Poland diabetes therapeutics market is expanding as a result of these events.

Market Restraints

Diabetes drugs can be costly, which can be a serious obstacle for patients who are unable to pay for their prescriptions. The expense of diabetes drugs may prevent the Polish market from expanding. The expansion of the market for branded drugs may be constrained by the accessibility of generic versions of diabetes medications. Since generic drugs are frequently less expensive than name-brand ones, the market for branded goods may decline. The development of the Poland diabetes therapeutics market can also be impacted by governmental rules and reimbursement practices. Regulation or reimbursement policy changes may put a cap on the number of diabetes drugs that are available or affordable.

Competitive Landscape

Key Players

• NEUCA (POL)
• Pharmacol (POL)
• Polska Grupa Farmaceutyczna (POL)
• Polpharma (POL)
• TZMO (POL)
• AstraZeneca
• Boehringer Ingelheim
• Eli Lilly
• GlaxoSmithKline
• Johnson Johnson
• Merck
• Novartis

Healthcare Policies and Regulatory Landscape

The Ministry of Health in Poland is the regulatory and policy-making authority in charge of establishing regulations governing the operation of the healthcare system, and large capital expenditures in healthcare, medical science, and education. The Ministry of Health has the authority to finance specific highly specialized health care services and specific public health programs in addition to ensuring that everyone has access to health care services paid for with public funds and regulating the structure and operation of universal health insurance through the issuance of ordinances based on statutory delegation. The Minister is in charge of the President of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products as well as the Main Pharmaceutical Inspector, Main Sanitary Inspector, Chemical Substances Inspector, and President. A pharmaceutical company submits a reimbursement application form to start a process that results in a Ministry of Health decision authorizing the payment of a medicinal product. The applicant bargains the cost of a product with a certain Ministry of Health division. The Ministry of Health's decision specifies the product's agreed-upon price as well as other parameters of reimbursement. Except for sales to hospitals, where a maximum price is set, the price is fixed at a particular amount. Furthermore, risk-sharing plans could be used for reimbursed goods (such as exclusive hospital conditions of sale), but unlike set prices, they are not made public.